Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 41
- Registration Number
- NCT01913379
- Locations
- 🇫🇷
SGS, Paris, France
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 55
- Registration Number
- NCT01911741
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Explore the Routes of Elimination of MDV3100
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 6
- Registration Number
- NCT01911715
- Locations
- 🇳🇱
PRA International, Zuidlaren, Netherlands
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT01911728
- Locations
- 🇿🇦
Parexel, George, South Africa
🇿🇦Parexel/Qdot Pharma, Port Elizabeth, South Africa
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 27
- Registration Number
- NCT01902251
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Colorado - Anschutz Medical Campus, Denver, Colorado, United States
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 33
- Registration Number
- NCT01901133
- Locations
- 🇲🇩
Arensia, Chisinau, Moldova, Republic of
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 594
- Registration Number
- NCT01887600
- Locations
- 🇪🇸
Site ES34011, Galdakao, Vizcaya, Spain
🇪🇸Site ES34003, Barcelona, Spain
🇺🇦Site UA38015, Kherson, Ukraine
A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 26
- Registration Number
- NCT01815684
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 86
- Registration Number
- NCT01799902
- Locations
- 🇧🇪
H.Hart Roeselaere, Roeselaere, Belgium
🇧🇪Maria Middelares, Gent, Belgium
🇧🇪AZ Damiaan, Oostende, Belgium
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT01797198
- Locations
- 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath